Labcorp is spinning out its clinical development unit in major shakeup – Endpoints News

Researchers use adeno-associated viruses (AAVs) as vehicles to deliver CRISPR/Cas systems, correct gene copies and DNA and RNA sequences into human cells as treatment modalities. But the size of the viruses themselves has been a limiting factor for cargo that can be stuffed into it. For instance, gene-editing technologies such as CRISPR/Cas and base editors must be divided into two adenoviruses.

Now, for the first time, scientists have engineered a way to shrink base editors, allowing them to be loaded into a single virus particle. David Liu, from MIT and Harvard’s Broad Institute, led the research and published a paper Thursday in Nature Biomedical Engineering.

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 146,600+ biopharma pros reading Endpoints daily — and it’s free.

Leave a Comment

Your email address will not be published.

%d bloggers like this: